What is Monobind?
Founded in 1978 and headquartered in Costa Mesa, California, Monobind Inc. has established itself as a leader in diagnostic development and innovation. The company specializes in the manufacturing of immunoassays, having produced over 200 million units, positioning it as one of the largest in-vitro diagnostic producers globally. Monobind's reach extends to over 30 countries, providing a comprehensive suite of assays, diagnostic tools, and biological raw materials to a diverse clientele including biomedical researchers, laboratories, manufacturers, and distributors. Renowned for its quality, reliability, and cost-effectiveness, Monobind leverages its pioneering experience and recognized R&D authority to deliver products that set industry standards in diagnostic healthcare.
How much funding has Monobind raised?
Monobind has raised a total of $898K across 2 funding rounds:
Debt
$350K
Debt
$548K
Debt (2020): $350K with participation from PPP
Debt (2021): $548K led by PPP
Key Investors in Monobind
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Monobind?
The recent major strategic investment signals Monobind's readiness for accelerated expansion and further innovation in the diagnostic healthcare sector. With a history spanning over four decades and a proven track record in assay manufacturing and global distribution, the company is well-positioned to capitalize on this capital infusion. Future endeavors will likely focus on enhancing its R&D capabilities, expanding its product portfolio, and strengthening its international market presence. This strategic financing is expected to fuel Monobind's continued leadership in providing high-quality, cost-effective diagnostic solutions.
See full Monobind company page
